Exploring the Market Shift to Oral Fluid Drug Testing


Monday, February 26, 2024
2:15 PM - 3:15 PM
Session Type: Workshop

This workshop will focus on the market shift to oral fluid; an emerging trend in the world of drug testing. We will touch on areas of science, technology, and safety with some emphasis on telehealth and the scientific rationale for why DOT is allowing oral fluid testing for the first time in history. Premier Biotech is an industry leader in oral fluid drug testing with expertise in rapid and lab-based options. As experts in the field, we will offer our lens into this alternative testing option for markets that were traditionally dependent exclusively on urine-based testing that required sending individuals out to external collection sites. We look forward to sharing knowledge that helps to cement the position of oral fluid as a solution for faster, easier drug testing.


Dr. Jennifer Colby, PhD, DABCC
Scientific Director, Premier Biotech

Dr. Jen Colby is the Scientific Director at Premier Biotech Labs, LLC, in Minneapolis, Minnesota. Dr. Colby received her bachelor’s degree in biology from Vanderbilt University, her PhD in toxicology from UC Berkeley, and completed a postdoctoral fellowship in clinical chemistry and toxicology at UCSF. Dr. Colby is certified by the American Board of Clinical Chemistry in clinical chemistry and toxicological chemistry and has directed toxicology laboratories of varying size in academia and industry. Dr. Colby has leadership roles in several professional organizations including SOFT, AACC, ABCC, and AAFS and she is an active peer reviewer for a number of journals. In her free time, she trains and competes in dressage with her horse Corleone (Cory).